American Capital Management Inc. Decreases Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

American Capital Management Inc. trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 14.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 248,853 shares of the company's stock after selling 42,414 shares during the quarter. IDEXX Laboratories comprises 4.1% of American Capital Management Inc.'s portfolio, making the stock its 6th biggest holding. American Capital Management Inc. owned 0.30% of IDEXX Laboratories worth $125,726,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Ridgewood Investments LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter worth $27,000. Institutional & Family Asset Management LLC bought a new stake in IDEXX Laboratories during the second quarter valued at about $28,000. E Fund Management Hong Kong Co. Ltd. grew its position in shares of IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock valued at $29,000 after purchasing an additional 57 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC increased its stake in shares of IDEXX Laboratories by 750.0% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company's stock worth $34,000 after purchasing an additional 60 shares during the period. Finally, Strategic Investment Solutions Inc. IL acquired a new position in shares of IDEXX Laboratories during the 2nd quarter worth about $36,000. 87.84% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. JPMorgan Chase & Co. lowered their target price on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a report on Friday, October 11th. Stifel Nicolaus lowered their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a research note on Thursday, October 10th. StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday. Piper Sandler reissued a "neutral" rating and issued a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Finally, Barclays dropped their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a report on Monday, November 4th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, IDEXX Laboratories presently has an average rating of "Moderate Buy" and an average target price of $552.38.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX traded down $0.01 during midday trading on Friday, reaching $421.75. 338,607 shares of the company's stock were exchanged, compared to its average volume of 672,036. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. The company's 50 day simple moving average is $451.91 and its two-hundred day simple moving average is $477.31. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The firm has a market capitalization of $34.54 billion, a PE ratio of 40.67, a price-to-earnings-growth ratio of 3.68 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping analysts' consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm had revenue of $975.50 million during the quarter, compared to analysts' expectations of $980.32 million. During the same quarter last year, the company earned $2.53 earnings per share. The company's revenue for the quarter was up 6.6% compared to the same quarter last year. Equities research analysts expect that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the transaction, the director now directly owns 905 shares of the company's stock, valued at $380,498.20. This trade represents a 27.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 2.11% of the company's stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.